换一批
换一批The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance.
作者：
主题词
抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);喜树碱(Camptothecin);结直肠肿瘤(Colorectal Neoplasms);费用效益分析(Cost-Benefit Analysis);氟尿嘧啶(Fluorouracil);随访研究(Follow-Up Studies);基因型(Genotype);德国(Germany);葡糖醛酸基转移酶(Glucuronosyltransferase);杂合子(Heterozygote);纯合子(Homozygote);人类(Humans);保险, 健康(Insurance, Health);醛氢叶酸(Leucovorin);肿瘤分期(Neoplasm Staging);预后(Prognosis);生活质量(Quality of Life);质量校正寿命(Quality-Adjusted Life Years);存活率(Survival Rate)
DOI
10.3109/0284186X.2015.1053983
PMID
26098842
发布时间
2018-12-02
- 浏览55
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
